A 340B View of Pluvicto (lutetium Lu 177 vipivotide tetetan): Financial Misalignment in Radioligand Therapy.

PURPOSE: This analysis offers an in-depth view of the financial potential and hurdles of radioligand therapies (RLT) for healthcare institutions covered under the 340B Drug Pricing Program. Using Pluvicto (lutetium Lu 177 vipivotide tetraxetan) as a case study, we aim to highlight the economic misalignment between healthcare institutions and radiation oncologists. METHODS: We provide an overview of the 340B program and performed a financial analysis of Pluvicto. This was achieved by identifying acquisition and reimbursement costs and comparing the Wholesale Acquisition Cost (WAC) to the calculated 340B ceiling price using HRSA formulas. Additionally, we compared physician work incentives by analyzing Medicare wRVU generation for a standard six-course of Pluvicto versus a 20-fraction External Beam Radiation Therapy (EBRT) plan. RESULTS: This analysis discovered that under the 340B program, covered entities can acquire Pluvicto at a discount of approximately 31.7% below the WAC ($34,970.71 vs. $51,168.13 per dose). This was shown to generate a potential gross margin of over $101,000 for a full six-dose course. Even with the large gross margin generated, we discovered that physician compensation remains disproportionately low. A full course of Pluvicto generates approximately 20.6 wRVUs compared to 47 wRVUs for a standard EBRT course. This creates a "wRVU trap" where radiation oncologists are financially penalized for the time-intensive training and management required for RLT. CONCLUSIONS: The 340B program offers significant revenue opportunities for hospitals administering RLTs like Pluvicto. However, current physician compensation models do not align with the clinical effort required. To ensure sustainable RLT adoption, health systems must leverage 340B margins to develop alternative incentive models that adequately compensate radiation oncologists for their role in this precision therapy.